B
Brett Rozeboom
Researcher at University of South Dakota
Publications - 4
Citations - 140
Brett Rozeboom is an academic researcher from University of South Dakota. The author has contributed to research in topics: Cancer & Metastatic breast cancer. The author has an hindex of 3, co-authored 3 publications receiving 59 citations.
Papers
More filters
Journal Article
The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies.
TL;DR: The most significant and updated research in clinical practice relevant to HER2+ BC management is summarized and the clinical status of upcoming anti- HER2 agents as well as immunotherapy drugs in combination with anti-HER2 agents are highlighted.
Journal Article
ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future.
TL;DR: Current treatment options, the molecular mechanisms that predispose to endocrine resistance, and a future pro-apoptotic treatment strategy for ER+ mBC patients are summarized and a discourse addressing the possibilities for novel combination strategy that can induce tumor cell apoptosis is presented.
Journal ArticleDOI
Active RAC1 Promotes Tumorigenic Phenotypes and Therapy Resistance in Solid Tumors.
TL;DR: It is argued that RAC1 plays a critical role in the progression of tumors and the development of resistance to various therapeutic modalities applied in the clinic, and the contextual mechanisms of Rac1 involvement in the developmentof resistance to cancer therapies are summarized.
Journal ArticleDOI
Association of pathologic response and survival after peri-operative therapy in resected pancreatic adenocarcinoma: KU cancer center experience.
Brett Rozeboom,Maximillian Martinez,Kathan Mehta,Ameer Hamza,Anusha Chidharla,Anwaar Saeed,Raed Al-Rajabi,Joaquina Baranda,Sean C. Kumer,Timothy M. Schmitt,Chris Lominska,A. Hoover,David Akhavan,Prasad Dandawate,Shrikant Anant,Subhrajit Saha,Ankita Tiwari,S. Bossmann,Weijing Sun,Anup Kasi +19 more
TL;DR: These findings warrant validation in a larger cohort as switch in adjuvant therapy could potentially change the treatment landscape for Pathologic Non-Responders, and found no statistical difference in DFS and OS between Pathologic Responders and Non- Responders to neo-adjuvant therapy.